Published in Hepatitis Weekly, September 11th, 1995
Under this agreement, Univax has exclusive worldwide rights to Chiron Biocine's vaccines for use as immunizing agents for the development of new human immunotherapeutic products. The collaboration capitalizes on the synergies from the concurrently announced proposed merger of Univax and North American Biologicals, Inc. (NABI) in manufacturing and commercializing...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Hepatitis Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.